Need professional-grade analysis? Visit stockanalysis.com
$8.03B
35.86
711
N/A
Arrowhead Pharmaceuticals Inc (ARWR) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $69.51, up 2.25% from the previous close.
Over the past year, ARWR has traded between a low of $12.36 and a high of $73.00. The stock has gained 462.4% over this period. It is currently 462.4% above its 52-week low.
Arrowhead Pharmaceuticals Inc has a market capitalization of $8.03B, with a price-to-earnings ratio of 35.86.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Side-by-side comparison against top Healthcare peers.